Welcome to our dedicated page for Sol Gel Tech news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Tech stock.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a dermatology company whose news flow centers on clinical trial progress, regulatory milestones, licensing transactions and financial updates related to its topical drug products and pipeline. The company developed TWYNEO, a fixed-dose combination cream for acne vulgaris, and EPSOLAY, a benzoyl peroxide cream for inflammatory lesions of rosacea, and continues to report on ex-U.S. approvals and commercialization agreements for these products.
Recent Sol-Gel news highlights include updates on its pivotal Phase 3 clinical trial of SGT-610 (patidegib gel 2%) for Gorlin syndrome, including completion of patient enrollment and expectations for future top-line results. The company also issues releases on exploratory work to extend SGT-610 into high-frequency basal cell carcinoma and on compassionate-use cases in patients with PTCH1-mutated lesions. For SGT-210, a topical erlotinib candidate for Darier disease and other rare hyperkeratinization disorders, Sol-Gel has reported on Phase 1b proof-of-concept data, trial design decisions and plans for feasibility studies in additional indications.
Investors following SLGL news will also find announcements on Health Canada’s approval of EPSOLAY, new license agreements with partners such as Searchlight Pharma, Viatris and regional distributors, and a product purchase agreement with a subsidiary of Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. Periodic financial results releases provide detail on revenue from licensing and royalties, research and development spending on SGT-610 and SGT-210, cash runway expectations and capital market developments such as the company’s reverse share split and Nasdaq listing status.
This news page aggregates these company-issued updates and related coverage, making it easier to track Sol-Gel’s clinical, regulatory and commercial milestones over time for its dermatology portfolio and rare disease pipeline.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will announce its third quarter 2020 financial results on November 12, 2020, at 7:05 AM ET. The company is a clinical-stage dermatology firm that specializes in developing branded and generic topical products for skin diseases. Their innovative microencapsulation technology is being used for products such as Twyneo and Epsolay, which are under investigation for acne vulgaris and papulopustular rosacea, respectively. Other pipeline projects include SGT-210, tapinarof, and roflumilast.
Sol-Gel Technologies (NASDAQ: SLGL) announced the FDA's acceptance of its New Drug Application (NDA) for Epsolay®, a topical cream targeting inflammatory lesions in rosacea. The PDUFA goal date is set for April 26, 2021, which could make Epsolay the first FDA-approved single-agent benzoyl peroxide prescription product. Results from Phase 3 trials, involving 733 patients, showed significant improvements in treatment outcomes compared to the vehicle. The adverse reactions were mostly mild to moderate, indicating a favorable safety profile.
Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology company, announced participation in upcoming virtual investor conferences. CEO Dr. Alon Seri-Levy will provide a company overview, while CFO Gilad Mamlok will represent Sol-Gel at the H.C. Wainwright Healthcare Conference on September 15, 2020, at 10:00 AM ET. Additionally, a fireside chat featuring Dr. Seri-Levy, Mr. Mamlok, and John Vieira is scheduled for the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:40 AM ET. Webcasts will be available on the company's website.
On September 3, 2020, Sol-Gel Technologies (NASDAQ: SLGL) reported that Bausch Health initiated a patent infringement lawsuit regarding Perrigo's ANDA for a generic version of Duobrii® lotion, which treats plaque psoriasis. Perrigo's application, filed on July 23, asserts that certain patents are invalid or will not be infringed. Duobrii® had annual sales of $88.4 million as of July 2020. Sol-Gel collaborates with Perrigo, sharing development costs and profits from the potential commercialization of the generic product.
Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2020 financial results, achieving $1.1 million in revenue, primarily from a collaboration with Perrigo. The company submitted a New Drug Application for Epsolay, aimed at treating subtype II rosacea, and is on track for another NDA submission for Twyneo in H2 2020. R&D expenses decreased to $6.5 million, down from $11.4 million year-on-year, while general and administrative costs rose to $2.2 million. Sol-Gel reported a net loss of $7.1 million, up from $4.9 million in Q2 2019. The company holds $66 million in cash and marketable securities, sufficient to fund operations into Q3 2021.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology firm, is set to report its second quarter 2020 financial results on August 6, 2020, at 7:05 AM ET. The company focuses on developing branded and generic topical drugs for skin diseases, utilizing its proprietary microencapsulation technology. Key products include Twyneo for acne vulgaris and Epsolay for rosacea. The pipeline also features early-stage and preclinical assets targeting various skin conditions.
Sol-Gel Technologies (NASDAQ: SLGL) announced an anticipated FDA approval of a generic drug in Q2 2021, following a partnership agreement. The brand's sales exceeded $180 million in 2019, indicating significant market potential. This launch could establish a new revenue stream for Sol-Gel in 2021, enhancing its financial outlook. CEO Alon Seri-Levy expressed optimism about the brand's entry into the market, emphasizing its potential benefits for the company's growth.
Sol-Gel Technologies (NASDAQ: SLGL) has expanded its collaboration with Perrigo Company for the development and commercialization of three new generic dermatology product candidates. Perrigo will pursue FDA approval and lead commercialization if successful. This partnership builds on previous agreements and is expected to generate significant revenue for Sol-Gel. Additionally, the company is focused on submitting NDAs for its branded candidates, Epsolay® and Twyneo®, later this year. However, a patent infringement issue has arisen involving Bausch Health regarding a generic version of Bryhali®.
Sol-Gel Technologies (NASDAQ: SLGL) will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 11:00 am Eastern Time. CEO Alon Seri-Levy will speak at the event. Investors can access a live audio webcast on the company's website, with a replay available for 30 days. Sol-Gel focuses on developing topical drug products for skin diseases, leveraging its microencapsulation technology. The company's pipeline includes treatments for acne and rosacea, along with other early-stage and preclinical assets.
Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming investor conferences. The Jefferies Virtual Healthcare Conference will feature CEO Dr. Alon Seri-Levy, CFO Gilad Mamlok, and U.S. Head of Commercialization John Vieira on June 2, 2020, at 11:00 am ET. Additionally, the Raymond James Human Health Innovation Conference will take place on June 18, 2020, with Dr. Seri-Levy speaking at 11:40 am ET. Live webcasts will be available on Sol-Gel's website, which will also host archived recordings for around 30 days post-event.